David Bond, MD, PhD

Associate Professor, Department of Psychiatry and Behavioral Sciences

David Bond

Contact Info


Office Phone 612-273-9120

Fax 612-273-9774

Office Address:
Department of Psychiatry
Laboratory for Neuropsychiatric Imaging
2312 S. 6th St.
Minneapolis, MN 55414

Mailing Address:
Department of Psychiatry & Behavioral Sciences
F282/2A West-B
8393A (Campus Delivery Code)
2450 Riverside Ave
Minneapolis, MN 55454

Administrative Assistant Name
Teneshia Collins

Administrative Email

MD, Memorial University of Newfoundland

Psychiatry Residency, Memorial University of Newfoundland

PhD in Neuroscience, University of British Columbia

BS, Memorial University of Newfoundland


Dr. Bond completed his BSc (First Class), MD, and Residency in Psychiatry at Memorial University of Newfoundland in St. John’s, Canada. He was a Clinical Instructor (from 2004-2007) and Assistant Clinical Professor (from 2007-2013) at the University of British Columbia Mood Disorders Center in Vancouver, Canada. While at UBC he also completed a PhD in Neuroscience. His PhD research involved used magnetic resonance brain imaging to investigate the relationship between obesity and brain illness progression in early-stage bipolar disorder. He joined the University of Minnesota Department of Psychiatry as an Associate Professor in 2014.


fMRI and other imaging, proteomics, bipolar disorder, 

Professional Associations

  • Canadian Medical Association
  • Canadian Network for Mood and Anxiety Treatments
  • International Society for Bipolar Disorders


Research Summary/Interests

Dr. Bond’s research interests include:

  1. Genetics of bipolar disorder (BD)
  2. Diagnostic tests for BD
  3. The relationship between body health and brain health in people with BD
  4. Cognitive functioning in BD
  5. The optimal use of medications in BD


Treatment guidelines:

1.Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW, Post RM, Berk M, et al. 2013. The International Society for Bipolar Disorders (ISBD) Task Force report on antidepressant use in bipolar disorders. American Journal of Psychiatry 170:1249-62.

2.Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Beaulieu S, Alda M, O'Donovan C, Macqueen G, McIntyre RS, Sharma V, Ravindran A, Young LT, Milev R, Bond DJ, et al. 2013. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disorders 15:1-44.

3.Bond DJ, Hadjipavlou G, Lam RW, McIntyre RS, Beaulieu S, Schaffer A, Weiss M. 2012. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder. Annals of Clinical Psychiatry 24:23-37.

4.McIntyre RS, Rosenbluth M, Ramasubbu R, Bond DJ, Taylor VH, Beaulieu S, Schaffer A. 2012. Managing medical and psychiatric comorbidity in individuals with major depressive disorder and bipolar disorder. Annals of Clinical Psychiatry 24: 163-169.

Selected journal articles (arranged chronologically):

1.Bond DJ, Silveira LE, MacMillan EL, Torres IJ, Lang DJ, Su W, Honer WG, Lam RW, Yatham LN. Diagnosis and body mass index effects on hippocampal volumes and neurochemistry in bipolar disorder. Translational Psychiatry, in press.

2.Bond DJ, Torres IJ, Lee SS, Kozicky JM, Silveira LE, Dhanoa T, Lam RW, Yatham LN. 2016. Lower cognitive functioning as a predictor of weight gain in early-stage bipolar disorder patients and healthy young adults: A 12-month study. Acta Psychiatrica Scandinavica: doi: 10.1111/acps.12674.

3.Bond DJ, Andreazza AC, Hughes J, Dhanoa T, Torres IJ, Kozicky JM, Young LT, Lam RW, Yatham LN. 2016. Association of peripheral inflammation with body mass index and depressive relapse in bipolar disorder. Psychoneuroendocrinology 65: 76-83.

4.Yatham LN, Beaulieu S, Schaffer A, Kauer-Sant’Anna M, Kapczinski F, Lafer B, Sharma V, Parikh S, Daigneault A, Qian H, Bond DJ, et al. 2015. Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double blind trial. Molecular Psychiatry 21: 1050-6.

5.Bond DJ, Ha TH, Lang DJ, Su W, Torres IJ, Honer WG, Lam RW, Yatham LN. 2014. Body mass index-related regional gray and white matter volume reductions in first-episode mania patients. Biological Psychiatry 76:138-45.

6.McGirr A, Bond DJ. 2014. Comprehensive pharmacologic management of bipolar depression. Current Treatment Options in Psychiatry; doi: 10.1007/s40501-014-0017-2.

7.Kozicky J, Torres IJ, Silveira LE Bond DJ, Lam RW, Yatham LN. 2014. Cognitive change in the year after a first manic episode: association between clinical outcome and cognitive performance early in the course of bipolar I disorder. Journal of Clinical Psychiatry 75: e587-93.

8.Muralidharan K, Ali M, Silveira L, Bond DJ, Fountoulakis KN, Lam RW, Yatham LN. 2013. Efficacy of second generation antipsychotics in treating acute mixed episodes in bipolar disorder: A meta-analysis of placebo-controlled trials. Journal of Affective Disorders 150:408-14.

9.Bond DJ, Lam RW, Yatham LN. 2010. The association of weight gain with mood symptoms and functional outcomes following a first manic episode: Prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). Bipolar Disorders 12: 616-626.

10.Bond DJ, Noronha MM, Kauer-Sant’anna M, Lam R, Yatham LN. 2008. Antidepressant-associated mood elevations in bipolar II disorder compared to bipolar I disorder and major depressive disorder: A systematic review and meta-analysis. Journal of Clinical Psychiatry 69: 1589-1601.

Selected book chapters (arranged chronologically):

1.Hadjipavlou G, Bond DJ, Yatham LN. 2012. Mood stabilisers in the treatment of bipolar II disorder. In Parker G, ed. Bipolar II Disorder: Modeling, Measuring and Managing, 2nd Edition. New York: Cambridge University Press.

2.Kusumakar V, Bond DJ, Yatham LN. 2009. Diagnosis and treatment of mania and hypomania. In Yatham LN and Kusumakar V, ed. Bipolar Disorder: A Clinician's Guide to Treatment Management, 2nd Edition. New York: Routledge.

3.Bond DJ, Vieta E, Tohen M. 2009. Antipsychotic medications in bipolar disorder: a critical review of randomized controlled trials. In Yatham LN and Kusumakar V, ed. Bipolar Disorder: A Clinician's Guide to Treatment Management, 2nd Edition. New York: Routledge.


Teaching Areas

For the past 15 years Dr. Bond has taught medical students, psychiatry residents, PhD students, and research fellows about the neurobiology, diagnosis, and treatment of bipolar disorder and associated conditions.


Clinical Interests

Dr. Bond’s clinical interests include the treatment of bipolar depression and the diagnosis and treatment of additional psychiatric conditions in people with bipolar disorder (e.g. anxiety disorders, attention deficit disorder). He has also co-authored a number of treatment guidelines for bipolar disorder.